首页 > 文献资料
-
miR-126、Transferrin、miR-133 b、miR-342和Cystatin C对2型糖尿病肾病的诊断价值
目的 探讨miR-126、Transferrin、miR-133b、miR-342和Cystatin C对2型糖尿病肾病的诊断价值.方法 选取2型糖尿病肾病患者30例为糖尿病肾病组,2型糖尿病非肾病患者30例为糖尿病非肾病组,同时选取健康体检者30例为对照组,检测3组受试者血清中miR-126和Transferrin的水平,尿中miR-133b、miR-342和Cystatin C的水平.用ROC曲线下面积分析miR-126、Transferrin、miR-133b、miR-342和Cystatin C对2型糖尿病肾病的诊断价值.结果 糖尿病肾病患者的miR-126的相对表达量明显低于糖尿病非肾病患者和健康体检者(P<0.05),而其miR-133b和miR-342的相对表达量、Cystatin C和Transferrin的表达量明显高于糖尿病非肾病患者和健康体检者(P<0.05).糖尿病非肾病患者miR-126的相对表达量明显低于健康体检者(P<0.05),而其miR-133b的相对表达量和Cystatin C和Transferrin的表达量明显高于健康体检者(P<0.05).2型糖尿病肾病患者与非2型糖尿病肾病人员的miR-126、miR-133b、miR-342、Cystatin C和Transferrin的灵敏度分别为96％、83％、70％、77％、83％;特异性分别为41％、75％、82％、88％、80％.四项联合检测的灵敏度为97％、特异性为77％,准确率为83％.结论 miR-126、Transferrin、miR-133b、miR-342和CystatinC可作为诊断2型糖尿病肾病的潜在标志物.
-
复合功能传递系统的结构、铁转递蛋白的传递联系和药物载体的磁性颗粒
This paper describes a new formulation of magnetic nanoparticles coated by a novel polymer matrixO-Carboxylmethylated Chitosan (O-CMC) as drug/gene carrier. The O-CMC magnetic nanoparticles were derivatized with a peptide sequence from the HIV-tat protein and transferrin to improve the translocational property and cellar uptake of the nanoparticles. To evaluate the O-MNPs-Tat-Tf as drug carriers, Methotrexate (MTX) was incorporated as a model drug and MTX-loaded O-MNPs-Tat-Tf with an average diameter of 75nm were prepared and characterized by TEM, AFM and VSM. The cytotoxicity of MTX-loaded O-MNPs-Tat-Tf was investigated with C6 cells. The results showed that the MTX-loaded O-MNPs-Tat-Tf retained significant antitumor toxicity; additionally, sustained release of MTX from O-CMC nanoparticles was observed in vitro, suggesting that the O-MNPs-Tat-Tf could be a novel magnetic targeting carrier. We also studied the ability of O-MNPs-Tat-Tf crossing BBB in rats by single photon emission computed tomography (SPECT).
